| 101 |
19417023 | PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells. | 2009 May 15 |
1 |
| 102 |
19549370 | [Apoptosis of Burkitt's lymphoma Raji cell line induced by bortezomib]. | 2009 Jun |
2 |
| 103 |
19553005 | MKP1 repression is required for the chemosensitizing effects of NF-kappaB and PI3K inhibitors to cisplatin in non-small cell lung cancer. | 2009 Dec 28 |
4 |
| 104 |
20046572 | Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma. | 2009 Jan-Feb |
1 |
| 105 |
18005386 | Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma. | 2008 Feb |
3 |
| 106 |
18083229 | Alkylating agents induce activation of NFkappaB in multiple myeloma cells. | 2008 Jul |
3 |
| 107 |
18083845 | Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemia. | 2008 Feb 15 |
6 |
| 108 |
18223231 | Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells. | 2008 Jan 15 |
2 |
| 109 |
18235046 | PRDM1 is involved in chemoresistance of T-cell lymphoma and down-regulated by the proteasome inhibitor. | 2008 Apr 1 |
1 |
| 110 |
18536579 | NF-kappaB in the pathogenesis and treatment of multiple myeloma. | 2008 Jul |
1 |
| 111 |
18549623 | [Proteasome inhibitor induces apoptosis and influences the expression of Notch1 and NF-kappaB in multiple myeloma RPMI8226 cells]. | 2008 Jun |
5 |
| 112 |
18684839 | Dynamic effect of bortezomib on nuclear factor-kappaB activity and gene expression in tumor cells. | 2008 Nov |
2 |
| 113 |
18813856 | Triptolide overcomes dexamethasone resistance and enhanced PS-341-induced apoptosis via PI3k/Akt/NF-kappaB pathways in human multiple myeloma cells. | 2008 Oct |
1 |
| 114 |
18826102 | [Proteasome inhibitor bortezomib sensitizes Hep-2 human laryngeal squamous cell carcinoma cells to ionizing radiation in vitro and in vivo]. | 2008 Jun |
1 |
| 115 |
18928584 | [Effects of proteasome inhibitor bortezomib on NF-kappaB activity and ICAM-1 mRNA expression of K562 cells]. | 2008 Oct |
6 |
| 116 |
18931595 | Simultaneous inhibition of the constitutively activated nuclear factor kappaB and of the interleukin-6 pathways is necessary and sufficient to completely overcome apoptosis resistance of human U266 myeloma cells. | 2008 Oct |
3 |
| 117 |
17032922 | PKC412 demonstrates JNK-dependent activity against human multiple myeloma cells. | 2007 Feb 15 |
1 |
| 118 |
17185461 | NF-kappaB-independent down-regulation of XIAP by bortezomib sensitizes HL B cells against cytotoxic drugs. | 2007 May 1 |
5 |
| 119 |
17237266 | Epidermal growth factor receptor inhibition sensitizes renal cell carcinoma cells to the cytotoxic effects of bortezomib. | 2007 Jan |
6 |
| 120 |
17332297 | A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study. | 2007 Mar 1 |
2 |
| 121 |
17352234 | The proteasome inhibitor bortezomib augments anti-proliferative effects of mistletoe lectin-I and the PPAR-gamma agonist rosiglitazone in human melanoma cells. | 2007 Jan-Feb |
1 |
| 122 |
17363600 | The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines. | 2007 Mar 15 |
1 |
| 123 |
17890907 | Inhibition of the canonical IKK/NF kappa B pathway sensitizes human cancer cells to doxorubicin. | 2007 Sep 15 |
2 |
| 124 |
17908991 | Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma. | 2007 Oct 1 |
4 |
| 125 |
18053191 | Bortezomib in combination with celecoxib in patients with advanced solid tumors: a phase I trial. | 2007 Dec 3 |
1 |
| 126 |
18186967 | Bortezomib inhibits osteoclast activity in patients with multiple myeloma. | 2007 Nov |
1 |
| 127 |
18225565 | Activity of bortezomib in adult de novo and relapsed acute myeloid leukemia. | 2007 Nov-Dec |
1 |
| 128 |
16223780 | NF-kappaB constitutes a potential therapeutic target in high-risk myelodysplastic syndrome. | 2006 Feb 1 |
2 |
| 129 |
16282346 | Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines. | 2006 May 1 |
3 |
| 130 |
16451401 | Cutaneous leucoclastic vasculitis (LV) following bortezomib therapy in a myeloma patient; association with pro-inflammatory cytokines. | 2006 Mar |
2 |
| 131 |
16537813 | Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation. | 2006 Jul 15 |
1 |
| 132 |
16546967 | SUMOylation plays a role in gemcitabine- and bortezomib-induced cytotoxicity in human oropharyngeal carcinoma KB gemcitabine-resistant clone. | 2006 Mar |
1 |
| 133 |
16621797 | Selective inhibition of endoplasmic reticulum-associated degradation rescues DeltaF508-cystic fibrosis transmembrane regulator and suppresses interleukin-8 levels: therapeutic implications. | 2006 Jun 23 |
2 |
| 134 |
16733806 | Bortezomib induces in HepG2 cells IkappaBalpha degradation mediated by caspase-8. | 2006 Jul |
2 |
| 135 |
16861900 | Proteasome inhibitor induces apoptosis through induction of endoplasmic reticulum stress. | 2006 Jul |
2 |
| 136 |
16904634 | Histone deacetylase inhibitor trichostatin A and proteasome inhibitor PS-341 synergistically induce apoptosis in pancreatic cancer cells. | 2006 Oct 6 |
1 |
| 137 |
17134969 | Bortezomib induces different apoptotic rates in B-CLL cells according to IgVH and BCL-6 mutations. | 2006 Nov |
2 |
| 138 |
18360602 | Bortezomib (Velcadetrade mark) in the Treatment of Multiple Myeloma. | 2006 Sep |
2 |
| 139 |
15878978 | The fully human anti-CD30 antibody 5F11 activates NF-{kappa}B and sensitizes lymphoma cells to bortezomib-induced apoptosis. | 2005 Sep 1 |
2 |
| 140 |
15963854 | PS-341-mediated selective targeting of multiple myeloma cells by synergistic increase in ionizing radiation-induced apoptosis. | 2005 Jul |
1 |
| 141 |
16005577 | Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma. | 2005 Dec 1 |
7 |
| 142 |
16081580 | Nuclear factor-kappaB pathway as a therapeutic target in head and neck squamous cell carcinoma: pharmaceutical and molecular validation in human cell lines using Velcade and siRNA/NF-kappaB. | 2005 Summer |
7 |
| 143 |
16316823 | Proteasome inhibition: a new approach for the treatment of malignancies. | 2005 Nov |
1 |
| 144 |
15016328 | Proteasome inhibitor PS-341 down-regulates prostate-specific antigen (PSA) and induces growth arrest and apoptosis of androgen-dependent human prostate cancer LNCaP cells. | 2004 Mar |
1 |
| 145 |
15070698 | The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance. | 2004 Apr 15 |
2 |
| 146 |
15073843 | Nuclear factor-kappaB modulation as a therapeutic approach in hematologic malignancies. | 2004 Apr 15 |
1 |
| 147 |
15090453 | Effects of the proteasome inhibitor PS-341 on tumor growth in HTLV-1 Tax transgenic mice and Tax tumor transplants. | 2004 Aug 1 |
1 |
| 148 |
15131062 | Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors. | 2004 May 1 |
2 |
| 149 |
15190257 | Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro. | 2004 Aug |
5 |
| 150 |
15210859 | Maximal apoptosis of renal cell carcinoma by the proteasome inhibitor bortezomib is nuclear factor-kappaB dependent. | 2004 Jun |
1 |